Genprex Inc (GNPX)

$0.28 -0.01 (-3.75%)
Market Cap 9.64M
Revenue (ttm) 0.00
Net Income (ttm) -21.11M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 556,400
Avg Vol 2,448,328
Day's Range N/A - N/A
Shares Out 33.15M
Stochastic %K 78%
Beta -0.50
Analysts Strong Buy
Price Target $7.50

Company Profile

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patient populations with unmet medical needs. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which uses lipid-based nanoparticles in a lipoplex form to deliver tumor suppressor gene-expressing plasmids to cancer ce...

Industry: Biotechnology
Sector: Healthcare
Phone: 877-774-4679
Address:
3300 Bee Cave Road, Suite 650-227, Austin, United States
Thorbig
Thorbig Jul. 11 at 9:49 PM
$GNPX No credibility in the CEO
1 · Reply
HawtDangus90
HawtDangus90 Jul. 11 at 8:18 PM
$GNPX they got wrecked so hard at INKT they Gota make a fraction of that back 😂😂
0 · Reply
HawtDangus90
HawtDangus90 Jul. 11 at 8:07 PM
$GNPX 😂
1 · Reply
HawtDangus90
HawtDangus90 Jul. 11 at 7:57 PM
$GNPX lol there it is
0 · Reply
HawtDangus90
HawtDangus90 Jul. 11 at 7:54 PM
$GNPX cover up shorty you watched all week for Friday to come and you made small potatoes 🥔
0 · Reply
HawtDangus90
HawtDangus90 Jul. 11 at 7:52 PM
$GNPX here comes that shorty dumping the rest of what he got today and will over right at 4pm
0 · Reply
History101
History101 Jul. 11 at 7:21 PM
$GNPX added. GLTALs!!
0 · Reply
HawtDangus90
HawtDangus90 Jul. 11 at 6:07 PM
$GNPX more shorts today then there has been all week looks like someone’s been watching and waiting to get their measly 3%
0 · Reply
Makessense
Makessense Jul. 11 at 5:03 PM
$INKT Next are: $GNPX and $BCTX .
0 · Reply
Carny
Carny Jul. 11 at 4:37 PM
$GNPX why do I have a feeling this is about to spike?
1 · Reply
Latest News on GNPX
Genprex Collaborators Present Positive Preclinical Research on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions

Jun 24, 2025, 9:25 AM EDT - 17 days ago

Genprex Collaborators Present Positive Preclinical Research on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions

Genprex Collaborators Present Research on Non-Viral Approach to Diabetes Gene Therapy Using Lipid Nanoparticle Delivery System at the 2025 American Diabetes Association 85th Scientific Sessions

Jun 23, 2025, 9:00 AM EDT - 18 days ago

Genprex Collaborators Present Research on Non-Viral Approach to Diabetes Gene Therapy Using Lipid Nanoparticle Delivery System at the 2025 American Diabetes Association 85th Scientific Sessions

Genprex to Participate at BIO 2025 International Convention

Jun 3, 2025, 7:00 AM EDT - 5 weeks ago

Genprex to Participate at BIO 2025 International Convention

Genprex to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting

May 29, 2025, 7:00 AM EDT - 6 weeks ago

Genprex to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting

Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting

May 28, 2025, 7:00 AM EDT - 6 weeks ago

Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting

Genprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 Diabetes

May 7, 2025, 7:00 AM EDT - 2 months ago

Genprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 Diabetes

Genprex Signs Exclusive License to Additional Gene Therapy Technology with UTHealth Houston for the Treatment of Glioblastoma

May 6, 2025, 7:00 AM EDT - 2 months ago

Genprex Signs Exclusive License to Additional Gene Therapy Technology with UTHealth Houston for the Treatment of Glioblastoma

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Ras Inhibitor Resistant Lung Cancer at the 2025 AACR Annual Meeting

Apr 30, 2025, 7:30 AM EDT - 2 months ago

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Ras Inhibitor Resistant Lung Cancer at the 2025 AACR Annual Meeting

Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting

Apr 29, 2025, 7:30 AM EDT - 2 months ago

Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting

Genprex Signs Exclusive Technology License Agreement with New York University Langone Health for the Treatment of Mesothelioma

Apr 28, 2025, 7:30 AM EDT - 2 months ago

Genprex Signs Exclusive Technology License Agreement with New York University Langone Health for the Treatment of Mesothelioma

Genprex Selected to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting

Apr 24, 2025, 8:15 AM EDT - 2 months ago

Genprex Selected to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting

Genprex Announces Research Collaborators' Abstract Published in Cancer Research Supplement Proceedings

Apr 22, 2025, 8:15 AM EDT - 2 months ago

Genprex Announces Research Collaborators' Abstract Published in Cancer Research Supplement Proceedings

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR Annual Meeting

Mar 26, 2025, 8:15 AM EDT - 3 months ago

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR Annual Meeting

Genprex Collaborators Selected to Present Positive Preclinical Data on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions

Mar 25, 2025, 8:15 AM EDT - 3 months ago

Genprex Collaborators Selected to Present Positive Preclinical Data on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions

Genprex to Participate at BIO Europe Spring 2025

Mar 4, 2025, 8:15 AM EST - 4 months ago

Genprex to Participate at BIO Europe Spring 2025

Genprex Advances Diabetes Program with Addition of Research Focused on Non-Viral Delivery System

Feb 19, 2025, 8:15 AM EST - 5 months ago

Genprex Advances Diabetes Program with Addition of Research Focused on Non-Viral Delivery System

Genprex Provides Update on Diabetes Gene Therapy Program

Feb 18, 2025, 8:15 AM EST - 5 months ago

Genprex Provides Update on Diabetes Gene Therapy Program

Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex® Delivery System is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung Cancer

Feb 13, 2025, 8:15 AM EST - 5 months ago

Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex® Delivery System is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung Cancer

Genprex Announces First Patient Dosed in Phase 2 Expansion Portion of Acclaim-3 Clinical Study of Reqorsa® Gene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer

Jan 23, 2025, 8:00 AM EST - 6 months ago

Genprex Announces First Patient Dosed in Phase 2 Expansion Portion of Acclaim-3 Clinical Study of Reqorsa® Gene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer

Genprex to Participate at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 6, 2025, 9:15 AM EST - 6 months ago

Genprex to Participate at the 43rd Annual J.P. Morgan Healthcare Conference

Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer

Dec 16, 2024, 9:15 AM EST - 7 months ago

Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer

Genprex Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for the Treatment of Lung Cancer

Nov 20, 2024, 9:29 AM EST - 8 months ago

Genprex Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for the Treatment of Lung Cancer

Genprex Collaborators Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting

Nov 5, 2024, 9:29 AM EST - 8 months ago

Genprex Collaborators Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting

Genprex to Participate in 2024 BIO Europe Conference

Oct 31, 2024, 9:29 AM EDT - 9 months ago

Genprex to Participate in 2024 BIO Europe Conference

Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer, Mesothelioma and Glioblastoma

Oct 28, 2024, 9:29 AM EDT - 9 months ago

Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer, Mesothelioma and Glioblastoma

Genprex Announces Sponsored Research Agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive

Oct 24, 2024, 9:29 AM EDT - 9 months ago

Genprex Announces Sponsored Research Agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive

Genprex Receives Safety Review Committee Approval to Advance to Highest Dose Group in Phase 1 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer

Oct 15, 2024, 9:29 AM EDT - 9 months ago

Genprex Receives Safety Review Committee Approval to Advance to Highest Dose Group in Phase 1 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Oct 10, 2024, 9:29 AM EDT - 9 months ago

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Genprex Collaborators to Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting

Oct 7, 2024, 9:29 AM EDT - 9 months ago

Genprex Collaborators to Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting

Genprex Featured in CEO/CFO Magazine Discussing Novel Gene Therapies for Cancer and Diabetes

Sep 23, 2024, 9:29 AM EDT - 10 months ago

Genprex Featured in CEO/CFO Magazine Discussing Novel Gene Therapies for Cancer and Diabetes

Genprex Announces Formation of Mesothelioma Clinical Advisory Board

Sep 19, 2024, 9:29 AM EDT - 10 months ago

Genprex Announces Formation of Mesothelioma Clinical Advisory Board

Genprex Announces Plans to Launch Separate Company to Focus on the Development of Gene Therapy to Treat Type-1 and Type-2 Diabetes

Sep 4, 2024, 9:29 AM EDT - 11 months ago

Genprex Announces Plans to Launch Separate Company to Focus on the Development of Gene Therapy to Treat Type-1 and Type-2 Diabetes

Genprex to Present and Participate at Upcoming September Investor and Industry Conferences

Sep 3, 2024, 8:15 AM EDT - 11 months ago

Genprex to Present and Participate at Upcoming September Investor and Industry Conferences

Genprex Releases New Video Featuring Chief Medical Officer Discussing Positive Patient Outcomes in Two Lung Cancer Clinical Trials

Aug 15, 2024, 9:30 AM EDT - 11 months ago

Genprex Releases New Video Featuring Chief Medical Officer Discussing Positive Patient Outcomes in Two Lung Cancer Clinical Trials

Genprex Announces Positive Clinical Study Updates from Acclaim-1 and Acclaim-3 Phase 1/2 Clinical Trials in Lung Cancer

Aug 14, 2024, 9:25 AM EDT - 11 months ago

Genprex Announces Positive Clinical Study Updates from Acclaim-1 and Acclaim-3 Phase 1/2 Clinical Trials in Lung Cancer

Genprex Granted Patent in Singapore for Reqorsa® Gene Therapy with PD-1 Antibodies to Treat Cancers

Aug 13, 2024, 8:31 AM EDT - 11 months ago

Genprex Granted Patent in Singapore for Reqorsa® Gene Therapy with PD-1 Antibodies to Treat Cancers

Genprex to Present at the August Sidoti Microcap Conference

Aug 8, 2024, 8:30 AM EDT - 1 year ago

Genprex to Present at the August Sidoti Microcap Conference

Genprex Issues Stockholder Letter and Provides 2024 Corporate Update

Jun 27, 2024, 8:31 AM EDT - 1 year ago

Genprex Issues Stockholder Letter and Provides 2024 Corporate Update

Genprex to Present at the 2024 BIO International Convention

May 30, 2024, 8:31 AM EDT - 1 year ago

Genprex to Present at the 2024 BIO International Convention

Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer

May 14, 2024, 8:31 AM EDT - 1 year ago

Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer

Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of Directors

May 13, 2024, 8:31 AM EDT - 1 year ago

Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of Directors

Genprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney Varner

May 8, 2024, 6:08 PM EDT - 1 year ago

Genprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney Varner

Genprex to Present and Participate at Upcoming May Investor and Industry Conferences

May 1, 2024, 8:31 AM EDT - 1 year ago

Genprex to Present and Participate at Upcoming May Investor and Industry Conferences

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting

Apr 9, 2024, 8:31 AM EDT - 1 year ago

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting

Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer

Apr 3, 2024, 8:31 AM EDT - 1 year ago

Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer

Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery System

Apr 2, 2024, 8:31 AM EDT - 1 year ago

Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery System

Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Mar 22, 2024, 4:10 PM EDT - 1 year ago

Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Mar 19, 2024, 1:24 PM EDT - 1 year ago

Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa® Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers

Mar 12, 2024, 9:01 AM EDT - 1 year ago

Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa® Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting

Mar 6, 2024, 8:30 AM EST - 1 year ago

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting

Thorbig
Thorbig Jul. 11 at 9:49 PM
$GNPX No credibility in the CEO
1 · Reply
HawtDangus90
HawtDangus90 Jul. 11 at 8:18 PM
$GNPX they got wrecked so hard at INKT they Gota make a fraction of that back 😂😂
0 · Reply
HawtDangus90
HawtDangus90 Jul. 11 at 8:07 PM
$GNPX 😂
1 · Reply
HawtDangus90
HawtDangus90 Jul. 11 at 7:57 PM
$GNPX lol there it is
0 · Reply
HawtDangus90
HawtDangus90 Jul. 11 at 7:54 PM
$GNPX cover up shorty you watched all week for Friday to come and you made small potatoes 🥔
0 · Reply
HawtDangus90
HawtDangus90 Jul. 11 at 7:52 PM
$GNPX here comes that shorty dumping the rest of what he got today and will over right at 4pm
0 · Reply
History101
History101 Jul. 11 at 7:21 PM
$GNPX added. GLTALs!!
0 · Reply
HawtDangus90
HawtDangus90 Jul. 11 at 6:07 PM
$GNPX more shorts today then there has been all week looks like someone’s been watching and waiting to get their measly 3%
0 · Reply
Makessense
Makessense Jul. 11 at 5:03 PM
$INKT Next are: $GNPX and $BCTX .
0 · Reply
Carny
Carny Jul. 11 at 4:37 PM
$GNPX why do I have a feeling this is about to spike?
1 · Reply
HawtDangus90
HawtDangus90 Jul. 11 at 2:37 PM
$GNPX let that guy who took out over 100k shorts this AM realize he’s not going to bring the price down anymore and get bored
1 · Reply
ClipSave
ClipSave Jul. 11 at 1:44 PM
$GNPX SMH. Give it all back day....
1 · Reply
TEMajor
TEMajor Jul. 10 at 7:21 PM
$GNPX ...another good day! Lets see how it closes.
0 · Reply
Rampart1
Rampart1 Jul. 10 at 2:55 PM
$NCL should move up. nice to see $GNPX slowly moving up also!
0 · Reply
Rampart1
Rampart1 Jul. 9 at 7:35 PM
$GNPX slow but go
0 · Reply
History101
History101 Jul. 9 at 6:42 PM
$GNPX my position is up 33% so far...GLTALs!!
0 · Reply
Chrisdamelio
Chrisdamelio Jul. 9 at 4:00 PM
$GNPX this shits for real don’t listen to all idiot haters
0 · Reply
Rampart1
Rampart1 Jul. 9 at 12:56 PM
$NCL on watch here with pennies like $PCSA and $MBRX moving and $GNPX ticking up.
0 · Reply
Makessense
Makessense Jul. 9 at 9:34 AM
$GNPX Can diabetes clinical trials begin "soon"? • Yes, if the FDA greenlights their IND application in 2025, an IND opening in the last quarter of 2025 or early 2026 is absolutely realistic. • Realistic expectations are that the first Phase 1 studies will begin in 2026—although this depends on FDA feedback and the completeness of their preclinical data. What do you think?
2 · Reply
Morslan
Morslan Jul. 8 at 10:33 PM
$GNPX RS, sell, don't wait. Out. Come back, maybe, when this deop to 1$ again. MAYBE.
1 · Reply
TEMajor
TEMajor Jul. 8 at 6:44 PM
$GNPX ...looking good today! Be nice if we can keep it going.
1 · Reply
Rampart1
Rampart1 Jul. 8 at 6:08 PM
$GNPX nice movement. $NCL on its way also.
0 · Reply